BRAF and colorectal carcinoma: Finally, to demonstrate that mut-BRAF CRC cells are especially sensitive to UPR, they were treated with two inhibitors of protein degradation pathways, the proteasomal inhibitor carfilzomib (CFZ) and the aggresome inhibitor ACY-1215, both of which are in clinical development and have been found to result in an overload of misfolded/damaged proteins and ER stress.